Introduction
Anticonvulsant drugs have a low therapeutic ratio so that dosage requirements are critical. Their effects are therefore susceptible to the influences of concurrent medication. In common with the anticonvulsants, the non-steroidal anti-inflammatory drugs tend to be highly protein bound and metabolized in the liver. Thus, potential (Richens, 1978) and azapropazone (Jones, 1976) (Monks and Richens, 1980) . Also, neither primidone nor its metabolite phenobarbitone are significantly protein bound (Richens, 1978) .
Impairment of hepatic metabolism is a more likely explanation particularly as phenytoin and phenobarbitone concentrations were both raised.
Over 40%. of an oral dose of azapropazone is metabolized by hydroxylation (Jones, 1976) in the liver, the remaining 60% is excreted unchanged in the urine. The related drugs phenylbutazone and oxyphenbutazone have both been reported as competing with phenytoin and phenobarbitone for hepatic hydroxylation (Hansten, 1979) . It is therefore quite possible that azapropazone could also compete for these enzyme systems. Low concentrations of serum folate have also been shown to impair the hepatic metabolism of anticonvulsants (Richens, 1978) and this may have been a contributory factor.
It is concluded that care should be exercised when prescribing azapropazone to patients receiving anticonvulsants.
